Table 1.

Demographic and clinicopathologic characteristics of study population

TotalResectableLAMetastatic
VariableN = 135n = 31n = 36n = 68P
Sexns
 Male85 (63%)17 (62%)24 (66%)44 (65%)
 Female50 (37%)14 (38%)12 (34%)24 (35%)
Age, median (range), y65.6 (39.2–87.3)67.9 (46.0–85.1)64.7 (40.5–84.6)66.9 (39.2–87.3)ns
Body mass index, (range), kg/m223.3 (14.5–42.3)24.3 (19.1–32.5)24.3 (16.7–38.2)22.2 (14.5–42.3)ns
Tumor locationns
 Head and isthmus94 (70%)24 (77%)24 (67%)46 (68%)
 Body18 (13%)3 (10%)5 (14%)10 (15%)
 Tail23 (17%)4 (13%)7 (19%)12 (17%)
Differentiation grade (n = 98)ns
 Well31 (32%)11 (35%)10 (43%)10 (23%)
 Moderate39 (40%)10 (32.5%)7 (31%)22 (50%)
 Poor28 (28%)10 (32.5%)6 (26%)12 (27%)
Baseline CA 19-9, median (range), IU/mL238.0 (0.6–636,000)26.0 (0.6–2,225)179.0 (1.0–10,970)2,748.0 (1.5–636,000)<0.001
  • NOTE: Bold italic font indicates statistically significant P value.

    Abbreviation: LA, locally advanced tumors.